Group 1 - Eli Lilly and Company will participate in Bernstein's 2nd Annual Healthcare Forum on September 25, 2025, with CFO Lucas Montarce engaging in a fireside chat at 8 a.m. Eastern time [1] - A live audio webcast of the event will be available on Lilly's investor website, with a replay accessible for approximately 90 days [2] - Eli Lilly has been pioneering life-changing discoveries for nearly 150 years, focusing on significant health challenges such as diabetes care, obesity treatment, Alzheimer's disease, immune system disorders, and difficult-to-treat cancers [3] Group 2 - The company has launched the "Brain Health Matters" campaign in partnership with Julianne Moore to encourage public awareness of brain health [4] - Eli Lilly introduced the TuneLab platform, which provides biotechnology companies access to AI-enabled drug discovery models, built through over $1 billion in research investment [5]

Core Viewpoint - Intermap Technologies reported a decline in second quarter revenue but achieved significant growth in operating cash flow, reaffirming its revenue projections for 2025 and highlighting advancements in its geospatial intelligence solutions [1][2][8]. Financial Performance - Second quarter revenue decreased from $3.6 million to $3.0 million year-over-year due to timing effects from Indonesia and a commercial contract [2]. - Operating cash flow for the quarter was $2.1 million, a significant improvement from a cash outflow of $500 thousand in the same quarter of 2024 [2]. - For the first half of 2025, operating cash flow increased by 22% to $1.4 million compared to the same period in 2024 [2]. Business Developments - The company is actively involved in Indonesia's Integrated Land Administration and Spatial Planning (ILASP) initiative, with recent funding agreements and trade agreements enhancing opportunities for digital trade and investment [3]. - Intermap's pipeline includes new multi-year opportunities across Southeast Asia, North America, South America, and the Middle East, despite some timing adjustments in U.S. Department of Defense contracts [4]. - The commercial insurance business is expanding, driven by the implementation of the Insurance Risk Assistant Subsystem (IRAS), which enhances property risk evaluation and reduces underwriting errors by up to 30% [5]. Outlook - The company reaffirms its projected 2025 revenue of $30–35 million and an EBITDA margin of 28%, with expectations to meet annual targets despite potential risks related to government tenders and product adoption [8]. Shareholder Information - A conference call is scheduled for today at 5:00 pm ET to discuss the financial results and provide updates [1][12].